US6610493B1
(en)
*
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
US5955317A
(en)
*
|
1993-01-25 |
1999-09-21 |
Takeda Chemical Industries, Ltd. |
Antibodies to β-amyloids or their derivatives and use thereof
|
PT730643E
(pt)
*
|
1993-10-27 |
2001-06-29 |
Lilly Co Eli |
Animais transgenicos portadores do alelo de app com mutacao sueca
|
US6365414B1
(en)
|
1994-08-26 |
2002-04-02 |
The General Hospital Corporation |
Vitro system for determining formation of Aβ amyloid
|
AU8083094A
(en)
*
|
1994-10-19 |
1996-05-15 |
General Hospital Corporation, The |
A diagnostic assay for alzheimer's disease: assessment of abeta abnormalities
|
US5972634A
(en)
|
1994-10-19 |
1999-10-26 |
The General Hospital Corporation |
Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities
|
US7427392B1
(en)
*
|
1994-11-14 |
2008-09-23 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
|
US6114133A
(en)
*
|
1994-11-14 |
2000-09-05 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
|
US5786180A
(en)
*
|
1995-02-14 |
1998-07-28 |
Bayer Corporation |
Monoclonal antibody 369.2B specific for β A4 peptide
|
EP0813411B1
(de)
*
|
1995-02-15 |
2002-01-23 |
Takeda Chemical Industries, Ltd. |
Verwendung von kompocedinderivaten zur inhibierung der bildung oder sekretion von beta-amyloid-protein
|
AU1832797A
(en)
*
|
1996-01-26 |
1997-08-20 |
Trustees Of Columbia University In The City Of New York, The |
A polypeptide from lung extract which binds amyloid-beta peptide
|
JP3816111B2
(ja)
*
|
1997-04-09 |
2006-08-30 |
インテレクト・ニューロサイエンシズ・インコーポレーテッド |
β−アミロイド末端に特異的な組換え抗体、それをコードするDNA及びその使用法
|
US8173127B2
(en)
*
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
US6207370B1
(en)
|
1997-09-02 |
2001-03-27 |
Sequenom, Inc. |
Diagnostics based on mass spectrometric detection of translated target polypeptides
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US7964192B1
(en)
*
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
AU2006202899B2
(en)
*
|
1997-12-02 |
2009-10-29 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidogenic disease
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
US20030147882A1
(en)
*
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US6699671B1
(en)
|
1998-09-24 |
2004-03-02 |
Pharmacia & Upjohn Company |
Alzheimer's disease secretase, APP substrates therefor, and uses therefor
|
KR100768381B1
(ko)
|
1998-09-24 |
2007-10-18 |
파마시아 앤드 업존 캄파니 엘엘씨 |
알츠하이머병 세크레타제
|
EP1939297A1
(de)
|
1998-09-24 |
2008-07-02 |
Pharmacia & Upjohn Company LLC |
Alzheimerkrankheit-Sekretase
|
US20040234976A1
(en)
*
|
1998-09-24 |
2004-11-25 |
Gurney Mark E. |
Alzheimer's disease secretase, app substrates therefor, and uses therefor
|
US6844148B1
(en)
*
|
1998-09-24 |
2005-01-18 |
Pharmacia & Upjohn Company |
Alzheimer's disease secretase, APP substrates therefor, and uses therefor
|
WO2000026251A2
(en)
*
|
1998-10-30 |
2000-05-11 |
Holtzman Jordan L |
A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
|
US7115410B1
(en)
|
1999-02-10 |
2006-10-03 |
Elan Pharmaceuticals, Inc. |
β-secretase enzyme compositions and methods
|
US7456007B1
(en)
|
1998-12-31 |
2008-11-25 |
Elan Pharmaceuticals, Inc. |
β-secretase enzyme compositions and methods
|
CA2361013A1
(en)
|
1999-01-25 |
2000-07-27 |
Minerva Biotechnologies Corporation |
Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
|
JP4653318B2
(ja)
|
1999-02-10 |
2011-03-16 |
エラン ファーマシューティカルズ,インコーポレイテッド |
βセクレターゼ酵素組成物および方法
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
AU780474B2
(en)
*
|
1999-06-16 |
2005-03-24 |
Boston Biomedical Research Institute Incorporated |
Immunological control of beta-amyloid levels in vivo
|
US20090162883A1
(en)
*
|
1999-09-23 |
2009-06-25 |
Pharmacia & Upjohn Company |
Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
|
US7514408B1
(en)
|
1999-12-02 |
2009-04-07 |
Elan Pharmaceuticals, Inc. |
β-secretase enzyme compositions and methods
|
WO2001096607A2
(en)
|
2000-06-13 |
2001-12-20 |
The Trustees Of Boston University |
Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing
|
US6686449B2
(en)
|
2000-06-30 |
2004-02-03 |
Pharmacia & Upjohn Company |
Mutant presenilin 1 polypeptides
|
WO2002036614A2
(en)
*
|
2000-11-01 |
2002-05-10 |
Insight Biotechnology Limited |
Peptides for use in the treatment of alzheimer's disease
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US6815175B2
(en)
|
2001-03-16 |
2004-11-09 |
Cornell Research Foundation, Inc. |
Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
|
US6906169B2
(en)
*
|
2001-05-25 |
2005-06-14 |
United Biomedical, Inc. |
Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
|
EP1448601A4
(de)
*
|
2001-11-02 |
2006-04-26 |
Diagenics Internat Corp |
Verfahren und zusammensetzungen von für beta-amyloide proteine spezifischen monoklonalen antikörpern
|
AR038568A1
(es)
*
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US7122374B1
(en)
*
|
2002-04-09 |
2006-10-17 |
Takaomi Saido |
Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
|
US20040049134A1
(en)
*
|
2002-07-02 |
2004-03-11 |
Tosaya Carol A. |
System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
|
EP1380290A1
(de)
*
|
2002-07-09 |
2004-01-14 |
Universitair Medisch Centrum Utrecht |
Cross-Beta-Strukturweg und seine therapeutische Relevanz
|
US20070003552A1
(en)
*
|
2002-07-09 |
2007-01-04 |
Gebbink Martijn F B |
Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
|
CA2487528A1
(en)
*
|
2002-07-24 |
2004-02-12 |
Innogenetics N.V. |
Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
|
EP1633786A4
(de)
*
|
2002-10-09 |
2007-07-25 |
Rinat Neuroscience Corp |
Verfahren zur behandlung der alzheimer-krankheit mit antikörpern gegen amyloid-beta-peptid und zusammensetzungen daraus
|
KR100520495B1
(ko)
*
|
2002-10-23 |
2005-10-11 |
한국과학기술연구원 |
베타아밀로이드 특이 단일 클론 항체 및 그의 제조방법
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
CA2513722A1
(en)
*
|
2003-02-01 |
2004-08-19 |
Neuralab Limited |
Active immunization to generate antibodies to soluble a-beta
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
EP1631561B1
(de)
|
2003-05-07 |
2010-08-18 |
General Electric Company |
Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid
|
US20040223912A1
(en)
*
|
2003-05-07 |
2004-11-11 |
Montalto Michael Christopher |
Compositions and methods for non-invasive imaging of soluble beta-amyloid
|
EP1480041A1
(de)
*
|
2003-05-22 |
2004-11-24 |
Innogenetics N.V. |
Verfahren zur Voraussage, zur Diagnose und zur vergleichenden Diagnose von Alzheimer
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
WO2005025616A1
(ja)
*
|
2003-09-09 |
2005-03-24 |
Takeda Pharmaceutical Company Limited |
抗体の用途
|
EP1717250A4
(de)
*
|
2004-02-20 |
2008-10-01 |
Immuno Biological Lab Co Ltd |
Monoklonaler antikörper und dessen verwendung
|
EP2298807A3
(de)
|
2004-07-30 |
2011-05-18 |
Rinat Neuroscience Corp. |
Gegen das Amyloid-beta-Peptid gerichtete Antikörper und Verfahren zu deren Anwendung
|
KR20070084170A
(ko)
*
|
2004-10-13 |
2007-08-24 |
아블린쓰 엔.브이. |
알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
|
WO2006066089A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
EP1838854B1
(de)
*
|
2004-12-15 |
2012-10-31 |
Janssen Alzheimer Immunotherapy |
Antikörper, die Amyloid-Peptide erkennen
|
TW200635608A
(en)
*
|
2004-12-15 |
2006-10-16 |
Neuralab Ltd |
Aβ antibodies for use in improving cognition
|
ES2259270B1
(es)
*
|
2005-03-09 |
2007-11-01 |
Consejo Superior De Investigaciones Cientificas |
Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
|
US20090202980A1
(en)
*
|
2005-03-21 |
2009-08-13 |
Crossbeta Biosciences B.V. |
Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
|
UY29504A1
(es)
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
US8067187B2
(en)
|
2005-07-13 |
2011-11-29 |
Crossbeta Biosciences B.V. |
Cross-β structure binding compounds
|
EP1907864A2
(de)
*
|
2005-07-13 |
2008-04-09 |
Crossbeta Biosciences B.V. |
Verfahren zur bestimmung der auswirkung einer behandlung auf den cross-beta struktur-gehalt eines proteins; auswahl von behandlungen und verwendungen davon
|
US8114832B2
(en)
*
|
2005-07-13 |
2012-02-14 |
Crossbeta Biosciences B.V. |
Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
|
CA2626783A1
(en)
*
|
2005-10-21 |
2007-05-03 |
Merck & Co., Inc. |
Anti-addl monoclonal antibody and use thereof
|
KR20080090408A
(ko)
|
2005-11-30 |
2008-10-08 |
아보트 러보러터리즈 |
항-Aβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
|
DK1976877T4
(en)
|
2005-11-30 |
2017-01-16 |
Abbvie Inc |
Monoclonal antibodies to amyloid beta protein and uses thereof
|
RU2551782C2
(ru)
*
|
2005-12-12 |
2015-05-27 |
Ац Иммуне Са |
Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
|
WO2007068429A1
(en)
|
2005-12-12 |
2007-06-21 |
F. Hoffmann-La Roche Ag |
Antibodies against amyloid beta 4 with glycosylated in the variable region
|
WO2007108675A1
(en)
*
|
2006-03-17 |
2007-09-27 |
Crossbeta Biosciences B.V. |
Methods of binding of cross-beta structures by chaperones
|
WO2009017467A1
(en)
|
2007-07-27 |
2009-02-05 |
Elan Pharma International Limited |
Treatment of amyloidogenic diseases
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
PL2046833T3
(pl)
*
|
2006-07-14 |
2014-01-31 |
Ac Immune Sa |
Humanizowane przeciwciało przeciw amyloidowi beta
|
US20100104577A1
(en)
*
|
2006-10-10 |
2010-04-29 |
Golde Todd E |
Methods and materials related to anti-a (beta) antibodies
|
US7745222B2
(en)
*
|
2006-10-13 |
2010-06-29 |
General Electric Company |
Amyloid binding assays
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
US7939075B2
(en)
|
2007-01-11 |
2011-05-10 |
Philipps-Universitaet Marburg |
Human monoclonal anti-amyloid-beta antibodies
|
EP1944315A1
(de)
*
|
2007-01-11 |
2008-07-16 |
Philipps-Universität Marburg |
Prophylaxe und Therapie von Morbus Alzheimer und anderen Demenzerkrankungen
|
WO2008096905A1
(ja)
|
2007-02-09 |
2008-08-14 |
Tokyo Metropolitan Organization For Medical Research |
抗brak(cxcl14)ヒトモノクローナル抗体及びその用途
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
CN101668525A
(zh)
|
2007-03-01 |
2010-03-10 |
前体生物药物股份公司 |
谷氨酰胺酰环化酶抑制剂的新用途
|
EP2142514B1
(de)
|
2007-04-18 |
2014-12-24 |
Probiodrug AG |
Thioharnstoffderivate als glutaminylcyclaseinhibitoren
|
RU2523894C2
(ru)
*
|
2007-04-18 |
2014-07-27 |
Янссен Альцгеймер Иммунотерапи |
Предупреждение и лечение церебральной амилоидной ангиопатии
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
KR20150055103A
(ko)
*
|
2007-06-12 |
2015-05-20 |
에이씨 이뮨 에스.에이. |
아밀로이드 베타에 대해 인간화된 항체
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
US8048420B2
(en)
*
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
ES2442500T3
(es)
*
|
2007-10-02 |
2014-02-11 |
Csl Limited |
Método de purificación de anticuerpos terapéuticos y método de uso
|
CA2701790A1
(en)
*
|
2007-10-05 |
2009-04-16 |
Ac Immune S.A. |
Use of humanized anti-beta-amyloid antibody in ocular diseases
|
US9403902B2
(en)
|
2007-10-05 |
2016-08-02 |
Ac Immune S.A. |
Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
EP2058001A1
(de)
*
|
2007-11-08 |
2009-05-13 |
Crossbeta Biosciences B.V. |
Steigerung der Immunogenizität von Antigenen
|
EP2058000A1
(de)
*
|
2007-11-08 |
2009-05-13 |
Crossbeta Biosciences B.V. |
Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
|
PE20091449A1
(es)
*
|
2007-12-11 |
2009-10-07 |
Glaxo Group Ltd |
Proteinas de union a antigenos
|
US20110104821A1
(en)
*
|
2008-05-08 |
2011-05-05 |
Takahiko Tokuda |
ABeta-OLIGOMER MEASUREMENT METHOD
|
US20110092445A1
(en)
*
|
2008-07-25 |
2011-04-21 |
Abbott Laboratories |
Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses
|
EP2149380A1
(de)
*
|
2008-07-29 |
2010-02-03 |
Medivet Pharma, S.L. |
Tierärztliche Immuntherapiezusammensetzung für altersbedingte kognitive Dysfunktion
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
EP2258398A1
(de)
*
|
2009-05-26 |
2010-12-08 |
Araclón Biotech, S. L. |
Albumin/Amyloidpeptid-Konjugate und deren Verwendungen
|
SG178953A1
(en)
|
2009-09-11 |
2012-04-27 |
Probiodrug Ag |
Heterocylcic derivatives as inhibitors of glutaminyl cyclase
|
SG10201405802UA
(en)
*
|
2009-09-18 |
2014-11-27 |
Probiodrug Ag |
Novel assay for the detection of amyloid beta peptides
|
ES2586231T3
(es)
|
2010-03-03 |
2016-10-13 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
DK2545047T3
(da)
|
2010-03-10 |
2014-07-28 |
Probiodrug Ag |
Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
|
JP2013523182A
(ja)
|
2010-04-15 |
2013-06-17 |
アボット・ラボラトリーズ |
アミロイドベータ結合タンパク質
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
JP6081356B2
(ja)
|
2010-07-30 |
2017-02-15 |
エーシー イミューン エス.エー. |
安全で機能的なヒト化抗βアミロイド抗体
|
CN105348387B
(zh)
|
2010-08-14 |
2020-08-25 |
Abbvie 公司 |
β淀粉样蛋白结合蛋白
|
ES2570167T3
(es)
|
2011-03-16 |
2016-05-17 |
Probiodrug Ag |
Derivados de benzimidazol como inhibidores de glutaminil ciclasa
|
WO2012131539A1
(en)
|
2011-03-31 |
2012-10-04 |
Pfizer Inc. |
Novel bicyclic pyridinones
|
EP2511296A1
(de)
|
2011-04-12 |
2012-10-17 |
Araclón Biotech, S. L. |
Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
US8906382B2
(en)
|
2011-07-19 |
2014-12-09 |
New York University |
Method for treating amyloid disease
|
US9926353B2
(en)
|
2011-07-19 |
2018-03-27 |
New York University |
Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
|
JP6043355B2
(ja)
|
2011-08-31 |
2016-12-14 |
ファイザー・インク |
ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
|
EP2852597B1
(de)
|
2012-05-04 |
2016-06-08 |
Pfizer Inc |
Heterocyclisch substituierte hexahydropyrano [3,4-d] [1,3] thiazin-amin-2-verbindungen als inhibitoren von app, bace1 bace und 2
|
CN105732639A
(zh)
|
2012-06-29 |
2016-07-06 |
辉瑞大药厂 |
作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
|
JP2015529239A
(ja)
|
2012-09-20 |
2015-10-05 |
ファイザー・インク |
アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
|
UA110688C2
(uk)
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
WO2014091352A1
(en)
|
2012-12-11 |
2014-06-19 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
|
US9403846B2
(en)
|
2012-12-19 |
2016-08-02 |
Pfizer Inc. |
Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
CA2897678A1
(en)
|
2013-02-13 |
2014-08-21 |
Pfizer Inc. |
Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
US9233981B1
(en)
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
MX2015010714A
(es)
|
2013-02-19 |
2016-06-14 |
Pfizer |
Compuestos de azabencimidazol.
|
US9102752B2
(en)
|
2013-03-15 |
2015-08-11 |
United Biomedical, Inc. |
Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
|
CA2925743C
(en)
|
2013-10-04 |
2018-03-06 |
Pfizer Inc. |
Novel bicyclic pyridinones as gamma-secretase modulators
|
EP3083618B1
(de)
|
2013-12-17 |
2018-02-21 |
Pfizer Inc |
Neuartige 3,4-disubstituierte-1h-pyrrolo[2,3-b]pyridine und 4,5-disubstituierte 7h-pyrrolo[2,3-c]pyridazine als lrrk2-hemmer
|
MD20160102A2
(ro)
|
2014-04-01 |
2017-04-30 |
Pfizer Inc. |
Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei
|
AP2016009493A0
(en)
|
2014-04-10 |
2016-10-31 |
Pfizer |
2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
|
EP3172210B1
(de)
|
2014-07-24 |
2020-01-15 |
Pfizer Inc |
Pyrazolopyrimidin verbindungen
|
KR102061952B1
(ko)
|
2014-08-06 |
2020-01-02 |
화이자 인코포레이티드 |
이미다조피리다진 화합물
|
PE20171318A1
(es)
|
2015-02-03 |
2017-09-07 |
Pfizer |
Ciclopropabenzofuranil-piridopirazindionas novedosas
|
WO2016203347A1
(en)
|
2015-06-17 |
2016-12-22 |
Pfizer Inc. |
Tricyclic compounds and their use as phosphodiesterase inhibitors
|
LT3313879T
(lt)
|
2015-06-24 |
2022-03-25 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš transferino receptorių su pritaikytu giminingumu
|
JP6873980B2
(ja)
|
2015-09-14 |
2021-05-19 |
ファイザー・インク |
LRRK2阻害薬としての新規のイミダゾ[4,5−c]キノリンおよびイミダゾ[4,5−c][1,5]ナフチリジン誘導体
|
WO2017051294A1
(en)
|
2015-09-24 |
2017-03-30 |
Pfizer Inc. |
N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
|
JP2018531924A
(ja)
|
2015-09-24 |
2018-11-01 |
ファイザー・インク |
テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用
|
WO2017051276A1
(en)
|
2015-09-24 |
2017-03-30 |
Pfizer Inc. |
N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
|
TWI819458B
(zh)
|
2015-10-02 |
2023-10-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
AU2017223132B2
(en)
|
2016-02-23 |
2019-12-05 |
Pfizer Inc. |
6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
|
CN109641898B
(zh)
|
2016-07-01 |
2022-04-08 |
辉瑞公司 |
用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
|
CA3056030A1
(en)
|
2017-03-10 |
2018-09-13 |
Pfizer Inc. |
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
|
IL269215B
(en)
|
2017-03-10 |
2022-09-01 |
Pfizer |
Disubstituted imidazole[4,5-c]quinoline derivatives
|
WO2018226992A1
(en)
|
2017-06-07 |
2018-12-13 |
Adrx, Inc. |
Tau aggregation inhibitors
|
AU2018287787A1
(en)
|
2017-06-22 |
2020-01-16 |
Pfizer Inc. |
Dihydro-pyrrolo-pyridine derivatives
|
EP3668886A2
(de)
|
2017-08-18 |
2020-06-24 |
Adrx, Inc. |
Peptidinhibitoren der tau-aggregation
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
HUE061533T2
(hu)
|
2018-03-23 |
2023-07-28 |
Pfizer |
Piperazin azaspiro származékok
|
AU2019304384A1
(en)
|
2018-07-17 |
2021-01-28 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-abeta antibody, antigen-binding fragment thereof and application thereof
|
EP4010367A4
(de)
*
|
2019-04-04 |
2023-10-11 |
The Royal Institution for the Advancement of Learning / McGill University |
Verwendung von ass34 zum bewerten von morbus alzheimer
|
JP7383043B2
(ja)
|
2019-11-19 |
2023-11-17 |
公益財団法人神戸医療産業都市推進機構 |
アミロスフェロイド(ASPD)の代替物となりうるアミロイドβタンパク質(Aβ)の架橋体、及びASPDの分析
|